Medical Condition News

RSS

PLC Systems' RenalGuard to be showcased at EuroPCR 2010

PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today announced that it will demonstrate RenalGuard® at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), May 25-28, 2010, in Paris, France. More than 11,000 clinicians and professionals are expected to attend this event.

21 May 2010

Clinical data evaluating CAL-101 in patients with hematologic malignancies to be presented at ASCO 2010

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase inhibitors for the treatment of cancer and inflammatory diseases, today announced that updated clinical data evaluating CAL-101, an oral, PI3K inhibitor, in patients with hematologic malignancies, will be presented during a poster discussion session at the 2010 American Society of Clinical Oncology Annual Meeting taking place June 4-8, 2010 at McCormick Place in Chicago, IL.

21 May 2010

Eli Lilly to honor individuals with Welcome Back Award for improving lives of others

Despite years of debilitating depression, multiple psychiatric hospitalizations and episodes of homelessness, Joseph Rogers refused to let mental illness and an unlucky adolescence blot out his potential imprint on the world. Despite once being branded unemployable, Joseph relishes his role as advocate, embracing the challenges of being a change agent in mental health legislation, and pioneering the peer-run services movement.

21 May 2010

Ligand Pharmaceuticals secures milestone and royalty interest in IL-9 antibody program

Ligand Pharmaceuticals Incorporated announced today that it has purchased from the Genaera Liquidating Trust certain intellectual property and interests in future milestones and royalties for MEDI-528, an IL-9 antibody program under development by AstraZeneca's subsidiary, MedImmune. MEDI-528 is currently in a 320-patient Phase II study for moderate-to-severe asthma.

21 May 2010

Tai Chi may help reduce stress, anxiety and depression

Tai Chi, a low impact martial art, has been associated with reduced stress, anxiety and depression, and enhanced mood, in both healthy people and those with chronic conditions.

21 May 2010

ArQule announces presentations on ARQ 197 c-Met inhibitor at 2010 ASCO

ArQule, Inc. today announced that the following presentations of clinical data for ARQ 197, a selective inhibitor of the c-Met receptor tyrosine kinase, will take place at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 4-8, 2010 in Chicago, Illinois.

21 May 2010

IGF1 drug improves nerve cell communication in PMS mouse model

Researchers from Mount Sinai School of Medicine have identified a drug that improves communication between nerve cells in a mouse model of Phelan-McDermid Syndrome (PMS).

21 May 2010

Information about tanning's damaging effect on appearance reduces sunbed use among young women

Information about the harm sunbeds can do to young people's appearance could make them less inclined to use the tanning devices, US scientists have found.

21 May 2010

New technique may improve treatments for heart disease

Spanish researchers have employed for the first time adult cells extracted from a human heart to turn stem cells from adipose tissue into cardiac myocytes. In other words, they achieved to "reprogram" adult stem cells, which might improve treatments for heart disease therapeutical.

21 May 2010

Red Cross survey: 68% of Americans involved in some kind of summer emergency

A new Red Cross survey shows that 68 percent of Americans have been involved in some kind of summer emergency, ranging from insect bites, heat stroke and broken bones to more life-threatening situations. One in every four people say they have been in a situation where someone needed CPR.

21 May 2010

Patients with VAD implants develop varying severities of AVWS

The findings of a 12 patient study recently published in Thrombosis and Haemostasis by University Medical Center Freiburg documented that patients implanted with a ventricular assist device (VAD) experienced a rapid onset of acquired von Willebrand syndrome (AVWS), while patients implanted with the SynCardia temporary Total Artificial Heart did not.

21 May 2010

Data on retreatment experiences with brentuximab vedotin in clinical trials to be presented at 2010 ASCO

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company today announced that data regarding retreatment experiences with brentuximab vedotin in phase I and phase II clinical trials will be presented during a poster session at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 4-8, 2010 in Chicago, Illinois.

21 May 2010

Study explores genetic imbalances that give rise to childhood brain tumors

The most comprehensive analysis yet of the genetic imbalances at the heart of childhood brain tumors known as high-grade gliomas (HGGs) identified a cancer gene that is unusually active in some tumors and is now the focus of a St. Jude Children's Research Hospital clinical trial.

21 May 2010

PTCL trial data on belinostat to be presented at 2010 ASCO Annual Meeting

Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in hematology and oncology, today announced that clinical data on belinostat will be presented at the 2010 Annual Meeting of the American Society of Clinical Oncology, to be held June 4-8, 2010 at the McCormick Place Convention Center in Chicago, Illinois, as part of the ASCO proceedings.

21 May 2010

Combination of reovirus and carboplatin/paclitaxel shows promising anticancer activity in SCCHN

Oncolytics Biotech Inc. announced today that abstracts covering clinical research with reovirus (REOLYSIN(R)) are available on the American Society of Clinical Oncology website at www.asco.org, and on the Oncolytics website at www.oncolyticsbiotech.com.

21 May 2010

Interim data from Phase 2 clinical trial of sapacitabine in patients with MDS to be presented at ASCO 2010

Cyclacel Pharmaceuticals, Inc. announced that new interim data from an ongoing, multicenter, Phase 2 clinical trial of oral sapacitabine, the Company's lead product candidate, will be presented at an oral poster discussion during the 2010 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois on Monday, June 7, 2010.

21 May 2010

New therapy program serves as foundation for ongoing clinical development

The researchers of the University of Helsinki, and Oncos Therapeutics, the biotech company developing new cancer therapeutics based on the next generation oncolytic viruses, published initial results from their Advanced Therapy Access Program in Cancer Research.

21 May 2010

Cancer Institute of New Jersey investigators target autophagy

In an effort to improve current anticancer treatments, investigators at The Cancer Institute of New Jersey (CINJ) have been targeting a process known as autophagy, in which cancer cells eat themselves as a measure of self preservation under chemotherapy and radiation stress, thus prolonging tumor cell survival and inducing resistance to therapy.

21 May 2010

Blood biomarker underscores role of inflammation in vascular disease

UC Davis researchers have discovered that a blood component linked with inflammation can predict coronary artery disease in African-Americans.

21 May 2010

Smoking cessation treatments effective and safe for people with schizophrenia

In a study published today in the journal Addiction, researchers have determined that treatment for smoking dependence is as effective among people with severe mental illnesses as it is for the general population. Importantly, they also found that offering such treatments does not appear to cause deterioration in mental health.

21 May 2010